Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study by Toshihiko Kinoshita et al.
ORIGINAL INVESTIGATION
Efficacy and safety of asenapine in Asian patients with an acute
exacerbation of schizophrenia: a multicentre, randomized,
double-blind, 6-week, placebo-controlled study
Toshihiko Kinoshita1 & Ya-Mei Bai2,3 & Jong-Hoon Kim4 & Mutsuo Miyake5 &
Nobuyuki Oshima5
Received: 24 September 2015 /Accepted: 9 April 2016 /Published online: 8 June 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Rationale Asenapine is a second generation anti-psychotic
approved in the USA in 2009 for the treatment of schizophre-
nia, but its efficacy has not been proven in Asian patients.
Objectives The objectives of this study are to evaluate the
efficacy and tolerability of asenapine in Asian patients
experiencing an acute exacerbation of schizophrenia.
Methods In this prospective, double-blind study, patients in
Japan, Korea, and Taiwan were randomized (1:1:1) to
asenapine 5 mg twice daily (bid), 10 mg bid or placebo for
6 weeks after a 3- to 7-day washout/screening period. The
primary endpoint was the mean change in the positive and
negative syndrome scale (PANSS) total score from baseline
to day 42/treatment end.
Results Of the 532 participants randomized, 530 received
treatment. The primary endpoint was significantly greater
with asenapine 5 and 10 mg bid than with placebo (−12.24
and −14.17 vs. −0.95; p < 0.0001). The results of secondary
endpoints including PANSS negative subscale scores and
PANSS responders at the end of treatment supported the re-
sults of the primary endpoint. There were no significant
differences in the incidence of treatment-emergent adverse
events reported with asenapine 5 and 10 mg bid and placebo
(84.6, 80.7, and 81.6 %). There was a mean (± standard devi-
ation) change in weight of −1.76 ± 2.45 kg for placebo, +0.42
± 2.65 kg for asenapine 5 mg bid, and +0.81 ± 2.89 kg for
asenapine 10 mg bid group.
Conclusions Asenapine was effective and generally well tol-
erated when used for the treatment of acute exacerbations of
schizophrenia in Asian patients.
Keywords Schizophrenia . Asenapine . Efficacy .
Tolerability
Introduction
Schizophrenia is a complex psychiatric disorder associated
with variable degrees of functional impairment and social dis-
ability (Lublin et al. 2005; Tandon et al. 2009). It is a chronic
relapsing disorder, with recurrent exacerbations of positive
symptoms against a background of persistent negative symp-
toms, cognitive dysfunction, and depressive symptoms
(Lublin et al. 2005; Tandon et al. 2009).
Anti-psychotic medication is the mainstay of treatment for
schizophrenia (van Os and Kapur 2009). Historically, pharma-
cological treatments have focused on dopamine D2 receptor
blockade to control the positive symptoms of schizophrenia,
while negative and cognitive symptoms often persist (Abi-
Dargham 2014; van Os and Kapur 2009). Second generation
anti-psychotics, which also inhibit a range of other receptors,
have been developed, but they vary in their effectiveness
across mood domains (Lublin et al. 2005; Pompili et al.
2011). In addition, second generation anti-psychotics have
differing levels of risk for weight gain and hyperprolactinemia
(De Hert et al. 2012; Kane 2011; Tandon et al. 2010), which
* Toshihiko Kinoshita
kinoshit@takii.kmu.ac.jp
1 Department of Neuropsychiatry, Kansai Medical University, 10-15
Fumizono-cho, Moriguchi, Osaka, Japan
2 Department of Psychiatry, Taipei Veterans General Hospital
(TPVGH), Taipei, Taiwan
3 Department of Psychiatry, College ofMedicine, National Yang-Ming
University, Taipei, Taiwan
4 Department of Psychiatry, Gachon University Gil Medical Center,
Gachon University School of Medicine, Incheon, Republic of Korea
5 MSD K.K., Tokyo, Japan
Psychopharmacology (2016) 233:2663–2674
DOI 10.1007/s00213-016-4295-9
can negatively affect treatment adherence (Kane 2011;
Lieberman et al. 2005).
Asenapine is a second generation anti-psychotic with a
unique receptor-binding profile that has been approved in
the USA for the treatment of schizophrenia (Citrome 2014a;
Shahid et al. 2009). It has antagonistic activity at dopaminer-
gic, serotonergic, α-adrenergic, and histaminic receptors but
no appreciable affinity for muscarinic receptors (Shahid et al.
2009). The efficacy and safety of asenapine in schizophrenia
has been established in a global clinical trial program (Citrome
2014b). In two 6-week fixed-dose trials, asenapine 5 mg twice
daily (bid) was more effective than placebo in improving pos-
itive and negative syndrome scale (PANSS) total scores (Kay
et al. 1987) in patients with acute exacerbations of schizophre-
nia, with only modest effects on weight and metabolic vari-
ables (Kane et al. 2010; Potkin et al. 2007).
In a dedicated study, the pharmacokinetic and safety pro-
files of asenapine were similar in healthy Japanese and
Caucasian subjects (Merck Sharp & Dohme B.V. 2014),
meaning no dosage adjustment is required on the basis of race.
However, generally Asian subjects account for only a small
percentage of the total populations enrolled in the phase II and
III clinical studies of asenapine, and studies conducted in spe-
cific ethnic populations are still needed. Therefore, the study
described herein was conducted to confirm the efficacy and




The study was conducted fromMay 2010 to April 2014 at 112
centers: Japan, 81 sites; Taiwan, 15 sites; and Korea, 16 sites.
Male and female patients aged 20–64 years with a Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition,
Text Revision (DSM-IV-TR) (American Psychiatric
Association 2000) diagnosis of schizophrenia of paranoid
(295.30), disorganized (295.10), catatonic (295.20), or undif-
ferentiated (295.90) subtypes were eligible for randomization.
The current acute exacerbation of schizophrenia had to be of
≤2 months duration, with symptoms that represented a dra-
matic and substantial change from the state prior to the exac-
erbation, and there was a requirement for a change in medica-
tion or dosage to treat new or worsened positive symptoms.
Other key inclusion criteria were a PANSS total score ≥60,
with scores of ≥4 in two or more of five items on the PANSS
positive subscale (delusions, conceptual disorganization, hal-
lucinatory behavior, grandiosity, suspiciousness/persecution)
at the initial screening assessment and at baseline, and a score
of ≥4 on the clinical global impressions-severity of illness
(CGI-S) scale (Guy 1976) at baseline. Patients who had
received previous anti-psychotic medication for a prior epi-
sode of acute exacerbation of schizophrenia were required to
have had a positive response. The use of all prohibited con-
comitant medications (anti-psychotics, anti-depressants,
mood stabilizers, anti-epileptics, monoamine oxidase inhibi-
tors, St. John’s Wort, anti-emetics that are dopamine antago-
nists, and traditional herbal medication) had to be
discontinued, with the last dose taken no later than the evening
prior to the baseline visit, for inclusion in the trial (for depot
neuroleptic, discontinuation must have occurred more than
3 months prior to randomization).
Patients with a diagnosis of schizoaffective disorder
(295.70), schizophrenia of residual subtype (295.60),
schizophreniform disorder (295.40), or a psychiatric disorder
other than schizophrenia were excluded from the study.
Women who were pregnant were ineligible for inclusion in
the trial. Patients were also excluded if they had taken any
experimental medication within 12 weeks before baseline,
were defined as having treatment-refractory schizophrenia,
had received treatment with ≥3 anti-psychotic drugs within
the previous month, or had an uncontrolled, unstable clinically
significant medical condition (e.g., renal, endocrine, hepatic,
respiratory, cardiovascular, hematologic, immunologic or ce-
rebrovascular disease, or malignancy) or abnormal laboratory,
vital sign, physical examination, or electrocardiogram (ECG)
findings at screening. Other exclusion criteria included the
following: current (past 6 months) substance abuse; a body
mass index (BMI) <16.0 or >35.0 at baseline; a diagnosis of
Parkinson’s disease; a history of or current treatment for nar-
row angle glaucoma; a history of any seizure disorder beyond
childhood; a history of allergy or sensitivity to drugs such as
psychotropics and anti-psychotics; a ≥20 % decrease in
PANSS total score from screening to baseline; imminent risk
of self-harm or harm to others; current involuntary inpatient
confinement; known diagnosis of borderline personality dis-
order, mental retardation, or organic brain disorder; and pre-
vious treatment with asenapine.
Patients classed as treatment-refractory (has been treated
with at least two different atypical anti-psychotic agents at
dosages equivalent to or greater than 600 mg/day of chlor-
promazine [12 mg/day of haloperidol] for more than 4 weeks,
each without clinical response, or has received clozapine for
12 weeks immediately preceding the screening) and those
who received treatment with three or more anti-psychotic
drugs, or dose equivalents higher than 18 mg/day of haloper-
idol (equivalent 900 mg/day of chlorpromazine) within
1 month prior to randomization were also excluded.
A number of measures were implemented to minimize the
risks to patients randomized to placebo: hospitalization for a
minimum 3 weeks, with the possibility of extending the hos-
pitalization to 6 weeks if the patient was not clinically stable
enough to be discharged; regular assessment of symptom se-
verity; requirement that a caregiver oversees the patient’s
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compliance with trial medication during outpatient dosing;
allowance of concomitant benzodiazepines to treat agitation
and anxiety; and exclusion of high-risk subjects including
those that are actively suicidal, homicidal, under involuntary
commitment, or have a recent history of aggressive behavior.
Randomization and treatment
The study consisted of a 3- to 7-day washout/screening period,
a 6-week double-blind treatment phase, and a follow-up peri-
od. Placebo was administered single blind for the duration of
the screening period, and patients were tapered off their pre-
study anti-psychotic medication, anti-depressant medication,
and any anti-parkinsonian drugs to treat extrapyramidal symp-
toms (EPS).
After the baseline assessments were completed, pa-
tients considered eligible by an investigator were ran-
domized (1:1:1) to receive sublingual asenapine 5 mg
bid, 10 mg bid, or placebo. The allocation of patients
was performed using permuted-block randomization
(block size of 6 and allocation ratio of 1:1:1) using
SAS. Participants and investigators remained blinded to
treatment assignment, in accordance with the double-
blind study design. The asenapine and placebo tablets
were identical in appearance and characteristics (i.e., all
tablets were fast dissolving) and had identical packag-
ing. During the treatment period, participants received
their allocated dosage of asenapine or placebo twice a
day every day for 6 weeks. Tablets were administered
sublingually without water.
Participants were hospitalized during screening and for the
first 3 weeks of the treatment period, with the possibility of
extending hospitalization to 6 weeks in the absence of a re-
sponsible caregiver to provide support and ensure compliance
with study medication. Compliance during inpatient treatment
was recorded by hospital staff and monitored by returned tab-
let counts during outpatient treatment.
Concomitant lorazepam and short-acting benzodiazepines
were permitted to treat agitation and anxiety, and concomitant
EPS medication was permitted if EPS worsened or appeared.
An interim analysis was built into the protocol to assess
whether the trial should be discontinued (in case of lack of
efficacy). In May 2012, an independent data-monitoring com-
mittee was convened to review the efficacy data for half of the
planned number of participants collected up to the day of
database lock (April 26, 2012). Upon review of the data, the
committee concluded that continuation of the trial was
appropriate.
Efficacy measurement
The primary efficacy outcome was change in the PANSS total
score from baseline to day 42 (end of treatment). Secondary
efficacy outcomes included changes from baseline to end of
treatment in PANSS subscale scores (positive symptoms, neg-
ative symptoms and general psychopathology), PANSS
Marder factor scores (positive symptoms, negative symptoms,
disorganized thought, hostility/excitement, anxiety/depres-
sion), and CGI-S scores. Additional secondary variables were
the percentage of PANSS responders (those with ≥30 % de-
crease in the total PANSS total score from baseline to end of
treatment) and the percentage of CGI-global improvement
(CGI-I) responders (those who are assessed as very much
improved, much improved or minimally improved by the in-
vestigator) at day 42. Post-baseline efficacy assessments were
obtained on day 4 and 7 and weekly thereafter (day 14, 21, 28,
35, and 42). Efficacy assessments were performed by an in-
vestigator or a trained rater assigned by the investigator. Using
the same rater for assessment of a subject throughout their
participation in the study was strongly encouraged.
Safety assessments
Key safety parameters were weight gain, body mass index
(BMI), EPS, glycosylated hemoglobin (HbA1c), fasting glu-
cose, insulin, and prolactin. For prolactin, only clinically rel-
evant abnormal values were reported. Other safety variables
were the frequency of the onset of treatment-emergent adverse
events (TEAEs) and clinically relevant changes in physical
findings, vital signs, electrocardiogram parameters, laboratory
values, and use of anti-parkinsonian drugs.
Laboratory, ECG, and BMI assessments were made at
baseline and on days 14, 28, and 42. Assessments of vital
signs were conducted at baseline and on days 14, 21, 28,
and 42. Physical examinations were conducted at screening
and at end of treatment (day 42). The incidence, nature, and
severity of AEs were recorded throughout the screening and
treatment periods until 7 days after the last dose of study drug.
EPS were reported as AEs and rated according to the drug-
induced extrapyramidal symptoms scale (DIEPSS) (Inada
2009) at baseline and on days 21 and 42.
Sample size calculations
Based on the results of previous phase II and III clinical trials
of asenapine in patients with schizophrenia (Minassian and
Young 2010; Potkin et al. 2007), the range of the difference
in the change in PANSS total score from baseline to end of
treatment at 42 days between the asenapine 5 mg bid and
placebo groups was between −3.4 and −9.7. Referring to the
study by Kane et al. (2010), we assumed that the change from
baseline in PANSS total score would be −6, and the standard
deviation (SD) of the total of change in PANSS score would
be 20 (effect size = 0.3). The sample size required to show
superiority of asenapine over placebo was estimated be 176
per group, with a two sided significance level of 5 and 80 %
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power. Therefore, approximately 530 participants were ex-
pected to be randomized.
Statistical analysis
Several sets were defined for the analysis of outcomes. The
subjects as treated (i.e., safety analysis set; All Subjects
Treated, AST) consisted of all participants enrolled in the
study who received at least part of one dose of the study drug,
while the full analysis set (FAS) consisted of all participants in
the AST who had a baseline and at least one post-baseline
PANSS measurement.
The primary efficacy outcome was analyzed in the FAS
using analysis of covariance (ANCOVA) with dropout or
missing data imputed by using the last observation carried
forward (LOCF). No patient had ≥6 missing PANSS items;
for 5 or fewer missing PANSS items, the PANSS score was
calculated by multiplying the total for the non-missing items
by the total number of items and then dividing by the number
of non-missing items.
The model included change from baseline in PANSS total
score as a response variable, baseline PANSS total score as a
covariate, and treatment groups and regions (Japan, Taiwan,
and Korea) as explanatory variables. Pairwise comparisons for
the primary efficacy outcome were performed in the following
order: (1) asenapine 5 mg bid vs. placebo and (2) asenapine
10 mg bid vs. placebo. The result of the second comparison
was considered only when the result of asenapine 5 mg bid vs.
placebo was statistically significant. Further analysis using a
mixed model for repeated measures (MMRM) was performed
using change from baseline in PANSS total score at each visit
from 7 days as the response variables and treatment groups,
regions, visits, and treatment by visit interaction as the fixed
effect variables and baseline PANSS total score as the covar-
iates. Changes from baseline to end of treatment in selected
secondary efficacy outcomes (PANSS subscale, Marder fac-
tor, and CGI-S scores) were also assessed using ANCOVA
with LOCF. The MMRM method was also performed for
PANSS subscale and Marder factor scores. PANSS and
CGI-I responder rates in the placebo versus each asenapine
group were compared using the Cochran-Mantel-Haenszel
(CMH) test with an adjustment for region. Regarding the anal-
ysis of secondary endpoints, these were exploratory in nature
and no adjustment for multiplicity was made. Safety variables
in the AST were summarized using descriptive statistics.
TEAEs and categorical variables for demographics were com-
pared the placebo and each asenapine group using Fisher’s
exact test. Continuous variables for demographics were com-
pared the placebo and each asenapine group using ANOVA.A
p value less than 0.05 was considered statistically significant
(two-tailed).
Results
Of a total of 573 patients screened, 532 participants were
randomized to treatment. The AST population included 530
participants (asenapine 5 mg bid: n = 175; asenapine 10 mg
bid: n = 181; placebo: n = 174) and the FAS included 525
participants (asenapine 5 mg bid: n = 173; asenapine 10 mg
bid: n = 178; placebo: n = 174). The flow of participants
throughout the study is presented in Fig. 1. A total of 303
participants completed treatment, with a greater percentage
of those in the asenapine 5 mg bid (65 %) or 10 mg bid
(60 %) groups completing the trial compared with those re-
ceiving placebo (46 %). The incidence of withdrawal due to
lack of efficacy was lower for participants receiving asenapine
5 mg bid (7.4 % of treated participants) or 10 mg bid (5.0 %)
than for those receiving placebo (15.5 %).
The key baseline characteristics of the AST population are
presented in Table 1. No meaningful differences in baseline
demographics or clinical characteristics including PANSS to-
tal scores were noted between the treatment groups. Of the
concomitantly used medications, all the groups (71.3 % in the
placebo, 62.9 % in the asenapine 5 mg bid, and 70.2 % in the
asenapine 10 mg bid.
Fig. 1 Patient disposition:
numbers of patients who were
screened, randomized to
treatment, received treatment, and
completed treatment, with reasons
for discontinuation shown
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bid (n = 175)
Asenapine 10 mg





Male 81 (46.6) 75 (42.9) 99 (54.7) 255 (48.1) 0.0722a
Female 93 (53.4) 100 (57.1) 82 (45.3) 275 (51.9)
Age, years 41.11 ± 12.27 41.41 ± 11.00 41.72 ± 11.10 41.42 ± 11.45 0.8844b
Bodyweight, kg 62.58 ± 12.62 62.51 ± 14.15 64.28 ± 13.18 63.14 ± 13.33 0.3670b
BMI, kg/m2 23.49 ± 3.88 23.64 ± 4.05 24.15 ± 4.42 23.76 ± 4.13 0.2895b
Region, n (%)
Japan 91 (52.3) 96 (54.9) 87 (48.1) 274 (51.7) 0.7846a
Taiwan 50 (28.7) 49 (28.0) 57 (31.5) 156 (29.4)
Korea 33 (19.0) 30 (17.1) 37 (20.4) 100 (18.9)
Schizophrenia (DSM-IV-TR) diagnosis, n (%)
Paranoid 137 (78.7) 139 (79.4) 138 (76.2) 414 (78.1) 0.9850a
Disorganized 13 (7.5) 14 (8.0) 14 (7.7) 41 (7.7)
Catatonic 4 (2.3) 3 (1.7) 4 (2.2) 11 (2.1)
Undifferentiated 20 (11.5) 19 (10.9) 25 (13.8) 64 (12.1)
Duration of current episode, n (%)
<2 weeks 47 (27.0) 34 (19.4) 32 (17.7) 113 (21.3) 0.1969a
≥2 weeks and <1 month 47 (27.0) 59 (33.7) 55 (30.4) 161 (30.4)
≥1 month and <2 months 80 (46.0) 81 (46.3) 94 (51.9) 255 (48.1)
≥2 months 0 1 (0.6) 0 1 (0.2)
PANSS total score 94.51 ± 17.26 94.15 ± 17.97 92.74 ± 17.34 93.79 ± 17.51 0.6049b
Concomitant medicationc, n (%)
Present 172 (98.9) 171 (97.7) 179 (98.9)
A02 drugs for acid related disorders
Magnesium oxide 24 (13.8) 16 (9.1) 27 (14.9)
A06 drugs for constipation
Sennoside a + b calcium 23 (13.2) 27 (15.4) 33 (18.2)
Sodium picosulfate 26 (14.9) 13 (7.4) 18 (9.9)
N02 analgesics
Paracetamol 24 (13.8) 20 (11.4) 21 (11.6)
N03 anti-epileptics
Clonazepam 20 (11.5) 10 (5.7) 7 (3.9)
Lorazepam 124 (71.3) 110 (62.9) 127 (70.2)
N05 psycholeptics
Olanzapine 26 (14.9) 21 (12.0) 19 (10.5)
Aripiprazole 18 (10.3) 18 (10.3) 10 (5.5)
Risperidone 28 (16.1) 25 (14.3) 15 (8.3)
Etizolam 22 (12.6) 27 (15.4) 21 (11.6)
Brotizolam 51 (29.3) 51 (29.1) 53 (29.3)
Flunitrazepam 18 (10.3) 13 (7.4) 15 (8.3)
Zolpidem 31 (17.8) 29 (16.6) 44 (24.3)
Zopiclone 28 (16.1) 28 (16.0) 33 (18.2)
N06 anti-depressants
Escitalopram 0 (0.0) 1 (0.6) 0 (0.0)
Escitalopram oxalate 0 (0.0) 1 (0.6) 0 (0.0)
Fluoxetine hydrochloride 1 (0.6) 0 (0.0) 0 (0.0)
Fluvoxamine maleate 0 (0.0) 0 (0.0) 1 (0.6)
Sertraline hydrochloride 0 (0.0) 0 (0.0) 1 (0.6)
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Primary efficacy outcome: PANSS total score
Mean PANSS total scores at baseline and at treatment end
(day 42) are shown in Table 2. The least squares mean
(LSM) changes from baseline in the PANSS total score at
end of treatment (day 42) in the FAS were −12.24 (95 %
confidence interval [CI] −15.28, −9.20), −14.17 (95 % CI
−17.12, −11.22) and −0.95 (95 % CI −3.95, 2.06) in the
asenapine 5 mg bid, asenapine 10mg bid, and placebo groups,
respectively. The improvements from baseline in PANSS total
score were significantly greater in participants receiving
asenapine 5 mg bid or asenapine 10 mg bid, compared with
placebo from days 14 and 7, respectively. Overall, the efficacy
profile of the asenapine 5 and 10 mg groups were similar
(Table 2). Analysis of the change in PANSS total score from
baseline over time using MMRM showed that improvements
from baseline in PANSS total score were significantly larger
in the asenapine 5 and 10 mg bid groups compared with pla-
cebo from day 14 and 7, respectively (p < 0.05) and were
sustained through to day 42 (Fig. 2). Table 3 describes the
proportion of responders using different thresholds to define
response (i.e., ≥20, ≥30, ≥40, and ≥50 % decrease in PANSS
total score).
Secondary efficacy outcomes
Positive and negative syndrome scale subscale scores
and responders
Changes in the PANSS subscale scores and PANSS Marder
factor scores supported the results of the primary efficacy
outcome analysis (Fig. 3a–h), whereby significantly more par-
ticipants were classified as PANSS responders (≥30 % de-
crease in score) at the end of treatment in the asenapine
5 mg bid (p = 0.0001) and 10 mg bid (p < 0.0001) groups
compared with the placebo group. This was evident for
PANSS positive, negative, and general scores and all
PANSS Marder subscores.
Clinical global impressions-severity of illness scores
and responders
CGI-S scores also supported the results of the primary efficacy
outcome analysis. The percentage of CGI-I responders at end
of treatment was significantly higher in both asenapine treat-
ment groups than in the placebo group (both p < 0.0001).
Safety and tolerability
There were no differences in the overall incidence of TEAEs
across the treatment groups; TEAEs were reported in 81.6 %
of participants receiving placebo, 84.6 % of participants re-
ceiving asenapine 5 mg bid, and 80.7 % of participants receiv-
ing asenapine 10 mg bid. Serious adverse events (SAEs) were
reported in 5.7 and 2.8 % of participants in the asenapine 5 mg
bid and 10 mg bid groups, and in 7.5 % of those receiving
placebo. No SAE occurred in more than one subject, apart
from aggravated schizophrenia, which occurred in 4.6 and
2.2 % of participants receiving asenapine 5 mg bid and
10 mg bid, respectively, and 4.6 % of the placebo group. As
per withdrawals for lack of efficacy, the incidence of with-
drawal due to adverse events (AEs) was lower for those re-
ceiving asenapine 5 mg bid (17.1 % of treated participants) or
10 mg bid (17.7 %), compared with those receiving placebo
(24.7 %).
Disease exacerbation and extrapyramidal symptoms
TEAEs occurring in ≥5 % of participants in any treatment





bid (n = 175)
Asenapine 10 mg




Bupropion 1 (0.6) 0 (0.0)) 1 (0.6)
Mirtazapine 2 (1.1) 0 (0.0) 0 (0.0)
Setiptiline maleate 0 (0.0) 1 (0.6) 0 (0.0)
Trazodone 2 (1.1) 0 (0.0) 2 (1.1)
Trazodone hydrochloride 1 (0.6) 0 (0.0) 1 (0.6)
All data are mean ± SD unless otherwise stated
BMI body mass index, DSM-IV Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, PANSS positive and negative
syndrome scale
a Fisher’s exact test
b ANOVA
cDrugs administered from the start of the double-blind treatment period to 7 days after the end of the study treatment (coded by WHODrug Dictionary)
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TEAEs for asenapine were aggravated schizophrenia,
akathisia, oral hypoesthesia, and somnolence. As shown in
Table 4, aggravated schizophrenia occurred in at least 10 %
of subjects in each treatment group but was less frequent in the
asenapine groups than in the placebo group. In contrast, rates
of EPS and akathisia were higher in participants receiving
asenapine 5 mg (5.1 and 11.4 %) and 10 mg (7.7 and
10.5 %) bid than in those receiving placebo (1.7 and 5.2 %).
The incidence rates of dizziness and increase in blood creatine
phosphokinase were higher in the asenapine 10 group, but
there were no differences in the other TEAEs between the
treatment groups (Table 4).
Weight
There was a mean (± standard deviation [SD]) change in
weight of −1.76 ± 2.45 kg for placebo, +0.42 ± 2.65 kg for
asenapine 5 mg bid, and +0.81 ± 2.89 kg for asenapine
10 mg bid. Clinically significant weight gain (≥7 % of base-
line body weight) was reported in 4.7 to 7.3 % of participants
in the asenapine groups and none in the placebo group. BMI
decreased by 0.66 ± 0.91 kg/m2 with placebo and increased by
0.16 ± 1.03 and 0.32 ± 1.09 kg/m2 with asenapine 5 mg bid
and 10 mg bid.
Laboratory values and vital signs
There were no clinically significant differences in laboratory
values and vital signs between the treatment groups. Mean ±
SD changes from baseline in insulin were 2.37 ± 14.08, 2.24
± 13.78, and 0.22 ± 20.34 μIU/mL with asenapine 5 mg bid
and 10 mg bid and placebo, respectively; mean ± SD changes
in fasting glucose were −0.03 ± 0.85, 0.11 ± 0.77, and 0.18 ±
0.97 mmol/L; and mean ± SD changes in HbA1c were
−0.01 % ± 0.41 %, −0.01 ± 0.49 % and −0.04 ± 0.45 %.
Mean ± SD changes from baseline in prolactin were
−17.92 ± 45.31, −13.27 ± 43.93 and −27.79 ± 46.25 μg/L
with asenapine 5 mg bid and 10 mg bid and placebo, respec-
tively. The percentage of participants who had normal prolac-
tin levels at baseline but levels above the reference range at the
end of treatment (day 42) was higher in those receiving
asenapine 5 mg bid (27.9 %) and asenapine 10 mg bid
(31.7 %) than in those receiving placebo (10.3 %).
Table 2 Positive and negative
syndrome scale total scores
during the study (full analysis set,




bid (n = 173)
Asenapine 10 mg






Mean 94.51 94.23 92.83
SD 17.26 18.06 17.42
End of treatment (day 42)
Mean 93.38 81.84 78.60
SD 25.30 26.10 25.01
Change from baseline to end of treatment
LSM −0.95 −12.24 −14.17 −11.29 −13.22
SE 1.53 1.55 1.50 2.10 2.09
95 % CI −3.95, 2.06 −15.28, −9.20 −17.12, −11.22 −15.42, −7.16 −17.33, −9.12
p valuea – – – <0.0001 <0.0001
a For between-group comparisons
bid twice daily, CI confidence interval, LSM least squares mean, SD standard deviation, SE standard error
Fig. 2 Primary efficacy outcome:
change from baseline in PANSS
total score over time (full analysis
set population). BL, baseline,
LSM least squares mean. *p <
0.05; **p < 0.01 vs. placebo
Psychopharmacology (2016) 233:2663–2674 2669
No adverse event related to QT prolongation (SMQ) was
observed during the monitoring of the current trial; however,
the data are not shown.
Stratified analyses
Given that the study was performed over a number of different
sites and countries, the potential for a country-by-treatment
interaction was examined, but no significant influences were
found (i.e., results were p > 0.05). Furthermore, stratified anal-
yses were performed for sex, disease duration, and schizo-
phrenia subtypes; the results of each indicated that there were
no demographic or disease subtype factors that influenced the
overall results.
Discussion
In this randomized, double-blind clinical trial, asenapine 5 and
10 mg bid was significantly more effective than placebo in
treating acute schizophrenia in Asian patients, as demonstrat-
ed by statistically significant improvements from baseline in
PANSS total scores. In addition, asenapine 5 and 10 mg bid
was effective in controlling both positive and negative symp-
toms, providing statistically significant improvements from
baseline in PANSS positive and negative scores compared
with placebo (by 11–13 points), as well as significant im-
provements in general scores and PANSS Marder 5 factor
scores. Moreover, the asenapine treatment groups showed sig-
nificant improvements versus placebo in other secondary ef-
ficacy variables (though it should be noted that these second-
ary variables were only part of an exploratory analysis); over-
all the efficacy profiles of the asenapine 5 and 10 mg groups
appeared to be similar. Asenapine was safe and well tolerated,
withminimal impact on bodyweight and no notable effects on
other metabolic parameters. The incidence of discontinuation
because of AEs or lack of efficacy was greater in the placebo
group than in the asenapine treatment groups. With the excep-
tion of elevated blood creatine phosphokinase and increased
dizziness, there were no differences between the 5 and 10 mg
groups for TEAEs.
Results of the current study, conducted in Asian countries,
complement the robustly positive results of two similarly de-
signed 6-week studies conducted in North America and
Europe in patients with an acute exacerbation of schizophrenia
(Kane et al. 2010; Potkin et al. 2007).While the study byKane
et al. found significantly greater reductions in mean PANSS
total scores, no significant difference from placebo was ob-
served in negative scores, or hostility/excitement subscores
(Kane et al. 2010). However, in our study, asenapine signifi-
cantly reduced the scores on the negative factor and hostility/
excitement factor, suggesting that asenapine has efficacy
across a broad range of symptoms in schizophrenia. Two other
short-term trials have been conducted with asenapine in the 5–
10 mg bid dose range: one was negative (active control, but
not asenapine, separated from placebo) and one failed (neither
asenapine nor active control separated from placebo) (Citrome
2014b; Szegedi et al. 2012). A meta-analysis of pooled data
from all four trials found asenapine to be superior to placebo
with regard to mean change in PANSS total score (Szegedi et
al. 2012). Both asenapine doses were safe and well tolerated,
with minimal effects on weight and no notable effects on
metabolic parameters, in all studies.
In one of the previous asenapine studies, a high placebo
response rate was reported; the authors suggested that this
may have contributed to the finding that asenapine 10 mg
Table 3 Responder rates for change in positive and negative syndrome scale (PANSS) total scores, across different threshold values. Responder




bid (n = 173)
Asenapine 10 mg






Responder, n (%) 52 (29.9) 92 (53.2) 91 (51.1) 23.3 21.2
95 % CI (%) 23.2, 37.3 45.5, 60.8 43.5, 58.7 13.2, 33.4 11.2, 31.2
≥30 % decrease
Responder, n (%) 36 (20.7) 68 (39.3) 78 (43.8) 18.6 23.1
95 % CI (%) 14.9, 27.5 32.0, 47.0 36.4, 51.4 9.2, 28.1 13.7, 32.6
≥40 % decrease
Responder, n (%) 21 (12.1) 41 (23.7) 56 (31.5) 11.6 19.4
95 % CI (%) 7.6, 17.9 17.6, 30.7 24.7, 38.8 3.7, 19.6 11.0, 27.8
≥50 % decrease
Responder, n (%) 8 (4.6) 25 (14.5) 40 (22.5) 9.9 17.9
95 % CI (%) 2.0, 8.9 9.6, 20.6 16.6, 29.3 3.8, 15.9 11.0, 24.8
bid twice daily, CI confidence interval
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bid did not have an advantage over placebo in that trial (Kane
et al. 2010). Low effect sizes versus placebo are also illustrat-
ed in the previously mentioned failed and negative studies,
reflecting the finding that placebo response tended to be larger
than historically expected (Szegedi et al. 2012). High placebo
response rates underscore the need to demonstrate that active
treatment can separate from placebo (Kane et al. 2010). In
order to exclude initial placebo responders in the present
study, oral placebo tablets were administered during the
screening period. Restriction of the duration of the current
acute exacerbation of schizophrenia to ≤2 months may have
contributed to the low placebo response rate and efficacy sep-
aration of the asenapine treatment groups from placebo seen in
this trial. In the present trial, asenapine 5mg bid and 10mg bid
were both found to be significantly effective in reducing
PANSS scores compared with placebo, which is clearly in line
with the previous pooled analysis of placebo-controlled trials
of asenapine in acute schizophrenia showing that the two
doses had similar efficacy (Friberg et al. 2009).
The results of the present study demonstrate that asenapine
is well tolerated, with rates of SAEs and withdrawals due to
Fig. 3 (continued)
Fig. 3 Secondary efficacy outcomes: changes from baseline in a PANSS
positive symptom factor, b PANSS negative symptom factor, c PANSS
general psychopathology score, d PANSS Marder positive symptom
factor, e PANSS Marder negative symptom factor, f PANSS Marder
disorganized thought factor, g PANSS Marder Hostility/Excitement
Factor, and h PANSS Marder anxiety/depression factor. BL baseline,
End end of treatment, LSM least squares mean, SD standard deviation.
*p < 0.05; **p < 0.01 vs. placebo
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AEs lower in both active treatment groups compared with
placebo. The AE profile of asenapine seen in this study was
as expected; reviews of the literature show that asenapine
treatment is associated with EPS and akathisia, increases in
prolactin versus placebo, oral hypoesthesia, and weight gain
(a known class effect) (Citrome 2014b), and the results report-
ed herein confirm that asenapine recipients experience these
AEs more frequently than those receiving placebo. However,
other active controlled studies suggest that the rates of EPS
and akathisia vary depending on the drug, and that asenapine
induces these events at a lower rate than some anti-psychotics
(Citrome 2014b). Similarly, the effect of asenapine on weight
has been reported as modest compared with other anti-
psychotics such as olanzapine (Citrome 2014b). In the present
study, only modest weight gain was observed in the asenapine
group. Asenapine’s unique functional activities at diverse neu-
rotransmitter receptors, including various serotonin receptors,
may contribute to the relatively benign effects on body weight
(Tarazi and Neill 2013).
Limitations of this study include the absence of an active
control arm and ethical questions regarding the use of placebo
in patients with acute schizophrenia. Another limitation of this
study was the reliance on pill counts to monitor adherence
rather than more reliable measures, such as measurement of
blood drug levels.
In conclusion, results of this double-blind, placebo-
controlled 6-week study showed that asenapine 5 mg bid
and 10 mg bid are effective and well tolerated in the
treatment of Asian patients with an acute exacerbation
of schizophrenia.
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